GlassScriptPhysician profile
John J Wittman
NPI 1366412892
$61,265.83
in general payments reported to CMS, 2019-2025
82 companies · $4,218 in 2025
The $4,218 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $14K · 2021: $4,997 · 2022: $9,435 · 2023: $9,940 · 2024: $4,727 · 2025: $4,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Honoraria: $3,750 · Consulting Fee: $1,500 · Travel and Lodging: $1,102 · Education: $91.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,441.35 |
| Honoraria | $3,750.00 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,101.67 |
| Education | $91.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $18,447.25 | 2019-2025 | |
| Sk Life Science, INC. | $12,158.01 | 2020-2025 | Xcopri |
| Allergan, INC. | $7,125.48 | 2019-2021 | |
| Ucb, INC. | $3,917.41 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $2,076.88 | 2019-2025 | Tysabri, Vumerity, Aduhelm |
| Abbvie INC. | $1,498.48 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Ceribell, INC. | $1,437.57 | 2024-2025 | Pocket Eeg Device |
| Sunovion Pharmaceuticals INC. | $962.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $897.29 | 2019-2025 | |
| Genzyme Corporation | $797.92 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $726.57 | 2019-2025 | Ultomiris, Soliris |
| Neurelis, INC. | $628.87 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $597.15 | 2019-2025 | |
| Livanova USA, INC. | $521.45 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $457.99 | 2019-2021 |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $444.04 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Emd Serono, INC. | $433.36 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $430.13 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $387.30 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $374.30 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Grifols USA, LLC | $362.99 | 2019-2025 | Gamunex-C |
| Lundbeck LLC | $361.83 | 2019-2025 | Rexulti, Vyepti |
| Amgen INC. | $334.16 | 2019-2025 | Uplizna, Aimovig |
| Harmony Biosciences LLC | $325.65 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $324.07 | 2022-2023 | Inspire |
| Pfizer INC. | $310.16 | 2021-2025 | |
| Celgene Corporation | $303.01 | 2021-2025 | Zeposia |
| Tg Therapeutics, INC. | $278.75 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $270.74 | 2021 | |
| Mdd US Operations, LLC | $266.82 | 2022-2025 | Gocovri, Gocovri |
| Argenx US, INC. | $236.63 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $217.69 | 2021-2023 | Uplizna |
| Avadel Cns Pharmaceuticals, LLC | $206.64 | 2024-2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $179.28 | 2021-2025 | Wainua, Andexxa |
| Banner Life Sciences, LLC | $169.89 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $165.58 | 2022-2025 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $164.03 | 2023-2024 | Aptiom |
| E.R. Squibb & Sons, L.L.C. | $148.91 | 2020-2024 | Zeposia |
| Insightec,INC | $135.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $118.78 | 2019-2025 | Qelbree |
| Catalyst Pharmaceuticals, INC. | $118.76 | 2021-2025 | Fycompa |
| Axsome Therapeutics, INC. | $117.78 | 2023-2025 | Sunosi, Symbravo |
| Csl Behring | $117.27 | 2019-2023 | Hizentra |
| Acadia Pharmaceuticals INC | $116.24 | 2019-2025 | Nuplazid |
| Mallinckrodt Hospital Products INC. | $114.87 | 2020-2023 | Acthar |
| Neurocrine Biosciences, INC. | $112.81 | 2020-2025 | Ingrezza |
| Kyowa Kirin, INC. | $96.99 | 2019-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $76.12 | 2022-2025 | Xeomin |
| Impel Pharmaceuticals INC. | $70.00 | 2022-2023 | Trudhesa |
| Merz North America, INC. | $69.13 | 2019-2020 | |
| Medtronic Vascular, INC. | $66.14 | 2019 | |
| Avanir Pharmaceuticals, INC. | $62.94 | 2019 | |
| Neuropace, INC. | $60.74 | 2022 | |
| Adamas Pharmaceuticals, INC. | $60.39 | 2019 | |
| Alnylam Pharmaceuticals INC. | $52.72 | 2021-2023 | Onpattro |
| Acorda Therapeutics, INC | $49.59 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $41.28 | 2022 | |
| Corium, LLC | $40.27 | 2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $38.40 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $36.29 | 2024 | Ponvory |
| Vertical Pharmaceuticals, LLC | $33.33 | 2019-2020 | |
| Promius Pharma LLC | $32.06 | 2019 | |
| Tersera Therapeutics LLC | $31.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $28.84 | 2025 | Dojolvi |
| Ge Healthcare | $28.41 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $25.87 | 2025 | Rexulti |
| Abbott Laboratories | $23.53 | 2019 | |
| Janssen Biotech, INC. | $22.44 | 2025 | |
| Akcea Therapeutics, INC. | $22.40 | 2019 | |
| Grt US Holding, INC. | $21.27 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.95 | 2022 | |
| Cycle Pharmaceuticals INC | $18.47 | 2024 | Tascenso Odt |
| Averitas Pharma INC. | $16.49 | 2025 | Qutenza |
| Bausch Health US, LLC | $16.40 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.75 | 2021 | |
| Octapharma USA, INC. | $13.65 | 2023 | Panzyga |
| Currax Pharmaceuticals LLC | $13.42 | 2021 | |
| Mallinckrodt Enterprises LLC | $13.28 | 2019 | |
| Resmed Corp | $13.05 | 2019 | |
| Aquestive Therapeutics, INC. | $12.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.